<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25883" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nifedipine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khan</surname>
            <given-names>Kashif M.</given-names>
          </name>
          <aff>University Hospitals/CWRU</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Jayesh B.</given-names>
          </name>
          <aff>University of Iowa Hospitals and Clinics</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schaefer</surname>
            <given-names>Timothy J.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kashif Khan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jayesh Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Timothy Schaefer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25883.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nifedipine is a calcium channel blocker in the dihydropyridine subclass. It is primarily used as an antihypertensive and as an anti-anginal medication. FDA-approved indications include chronic stable angina, hypertension. It also has other off-label indications. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, monitoring, and toxicity of nifedipine, so providers can direct patient therapy successfully in instances where nifedipine provides a benefit to patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of nifedipine.</p></list-item><list-item><p>Discuss the therapeutic mechanism of action of nifedipine.</p></list-item><list-item><p>Summarize the adverse event profile associated with nifedipine therapy.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with nifedipine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25883&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25883">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25883.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nifedipine is a calcium channel blocker that belongs to the dihydropyridine subclass. It is primarily used&#x000a0;as an antihypertensive and antianginal medication.</p>
        <p><bold>FDA Approved Indications</bold>[<xref ref-type="bibr" rid="article-25883.r1">[1]</xref><xref ref-type="bibr" rid="article-25883.r2">[2]</xref><xref ref-type="bibr" rid="article-25883.r2">[2]</xref><xref ref-type="bibr" rid="article-25883.r3">[3]</xref><xref ref-type="bibr" rid="article-25883.r4">[4]</xref><xref ref-type="bibr" rid="article-25883.r5">[5]</xref><xref ref-type="bibr" rid="article-25883.r6">[6]</xref></p>
        <list list-type="order">
          <list-item>
            <p><bold>Chronic stable angina&#x000a0;</bold>- Nifedipine reduced the frequency of angina and increased the mean exercise time in the IMAGE trial. Reflex tachycardia may limit its effectiveness; the addition of a beta-blocker can overcome this limitation. A&#x000a0;long-acting formulation is preferred (extended-release).&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Vasospastic angina&#x000a0;</bold>- It can be used as a second line of treatment.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Hypertension&#x000a0;</bold>-&#x000a0;May be used as monotherapy or in combination with several different medications to manage hypertension (such as ACE inhibitor, ARB, thiazide diuretic).</p>
          </list-item>
        </list>
        <p>
<bold>Off-label Uses</bold>
<xref ref-type="bibr" rid="article-25883.r7">[7]</xref>
<xref ref-type="bibr" rid="article-25883.r8">[8]</xref>
<xref ref-type="bibr" rid="article-25883.r9">[9]</xref>
<xref ref-type="bibr" rid="article-25883.r10">[10]</xref>
<xref ref-type="bibr" rid="article-25883.r11">[11]</xref>
</p>
        <list list-type="order">
          <list-item>
            <p>Raynaud phenomenon</p>
          </list-item>
          <list-item>
            <p>Severe hypertension during pregnancy and post-partum hypertension</p>
          </list-item>
          <list-item>
            <p>High altitude pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Pulmonary arterial hypertension&#x000a0;(group 1)</p>
          </list-item>
          <list-item>
            <p>Achalasia</p>
          </list-item>
          <list-item>
            <p>Distal ureteric calculi</p>
          </list-item>
          <list-item>
            <p>Tocolysis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25883.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>During the depolarization phase of smooth muscle cells, there is an influx of calcium ions through voltage-gated channels. Nifedipine inhibits the entry of calcium ions by blocking these voltage-dependent L-type calcium channels in&#x000a0;vascular smooth muscle and myocardial cells. Reduced intracellular calcium reduces&#x000a0;peripheral arterial vascular resistance and dilatation of coronary arteries, leading to a reduction in systemic blood pressure and increased myocardial oxygen delivery. Nifedipine thus has hypotensive and antianginal properties.</p>
      </sec>
      <sec id="article-25883.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nifedipine is available in both immediate and extended-release preparations. Its initial marketing was in a short-acting, immediate-release formulation that required multiple daily dosing. These preparations caused rapid vasodilation followed by reflex sympathetic activation, resulting in side effects such as headaches, palpitations, and flushing. These side effects led to the launch of extended-release preparations, which have shown to have a sustained 24-hour anti-hypertensive effect and fewer side effects.</p>
        <p>Extended-release preparations are available in 30, 60, and 90 mg tablets.&#x000a0;Dosage adjustments should ideally occur at 7- to 14-day intervals. The same total daily dosage should apply when switching from immediate to extended-release preparations. Patients may take immediate-release formulations without regard to meals. A few specific extended-release preparations require ingestion on an empty stomach.&#x000a0;</p>
        <p>Immediate-release preparations have an onset of action within 20 minutes with a plasma half-life of about 4 to 7 hours. Extended-release preparations have an approximate duration of action of about 24 hours. &#x000a0;It undergoes hepatic metabolism via the CYP3A4 pathway. Extended-release preparations have a bioavailability of up to 89% relative to the immediate-release formulation. Bioavailability significantly increases in patients with liver failure necessitating dosage adjustment (due to reduced clearance of the medication).&#x000a0;</p>
        <p>
<bold>Recommended Dosages</bold>
</p>
        <p>
<bold>Chronic Stable Angina</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate-release: 10 to 20 mg three times daily;&#x000a0;maximum dose of 180 mg per day</p>
          </list-item>
          <list-item>
            <p>Extended-release: 30 or 60 mg daily;&#x000a0;maximum dose of 120 mg per day</p>
          </list-item>
        </list>
        <p>
<bold>Vasospastic Angina</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release: 30 or 60 mg daily;&#x000a0;maximum dose of 120 mg per day</p>
          </list-item>
        </list>
        <p>
<bold>Hypertension</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release: 30 or 60 mg daily;&#x000a0;maximum dose of 120 mg per day&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Hypertensive Emergency During Pregnancy or Postpartum Period</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Immediate-release: 10 mg; may repeat with a 20 mg dose in 20 minutes&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25883.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects present in about 20&#x000a0;to 30% of patients prescribed nifedipine. These are primarily&#x000a0;the result of the vasodilatory properties of nifedipine.</p>
        <p>The most common adverse effects include flushing,&#x000a0;peripheral edema, dizziness, headache. Tolerance is better with the extended-release preparations than the immediate-release preparations of nifedipine.&#x000a0;Hypersensitivity reactions, such as pruritus, urticaria, and bronchospasms, are relatively rare.&#x000a0;Abrupt discontinuance of the drug after prolonged use&#x000a0;may lead to&#x000a0;rebound hypertension or angina.&#x000a0;</p>
      </sec>
      <sec id="article-25883.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity to nifedipine or its components</p>
          </list-item>
          <list-item>
            <p>ST-elevation myocardial infarction&#x000a0;<xref ref-type="bibr" rid="article-25883.r12">[12]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe aortic stenosis</p>
          </list-item>
          <list-item>
            <p>Unstable angina</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Heart failure</p>
          </list-item>
          <list-item>
            <p>Moderate to severe hepatic impairment</p>
          </list-item>
        </list>
        <p>In patients with unstable angina/non-STEMI, the use of immediate-release nifedipine is not a recommendation except with concomitant beta-blockade.<xref ref-type="bibr" rid="article-25883.r13">[13]</xref> Immediate-release preparations of nifedipine (sublingually or orally) should be avoided&#x000a0;in patients within hypertensive emergencies and urgencies as it is neither safe nor effective.<xref ref-type="bibr" rid="article-25883.r14">[14]</xref> In cardiogenic shock, the heart cannot pump effectively, and this situation is exacerbated by inhibiting the influx of calcium ions into cardiac cells.<xref ref-type="bibr" rid="article-25883.r13">[13]</xref> In severe aortic stenosis, nifedipine can cause ventricular collapse and dysfunction. In unstable angina, nifedipine causes a reflexive increase in cardiac contractility, which increases myocardial oxygen demand and worsens the ischemia. Nifedipine can exacerbate hypoperfusion to vital organs in patients with severe hypotension.<xref ref-type="bibr" rid="article-25883.r13">[13]</xref> Furthermore, patients with hepatic impairment may not be able to&#x000a0;metabolize nifedipine, leading to a longer half-life, putting them at an increased risk of toxicity and side effects.&#x000a0;</p>
      </sec>
      <sec id="article-25883.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In general, there is no required laboratory monitoring for patients taking nifedipine. Since nifedipine is an antihypertensive medication, clinicians and patients should regularly measure blood pressure to achieve target levels. Patients should undergo monitoring for adverse side effects such as peripheral edema, dizziness, flushing.&#x000a0;</p>
      </sec>
      <sec id="article-25883.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Treatment of overdose varies with the amount taken, duration since ingestion, age and, co-morbidities of the patient. Initial assessment involves securing airway, breathing, circulation, appropriate&#x000a0;blood work, including testing for coingestants. Early consultation with poison control/ toxicology should be a priority.</p>
        <p>An overdose of nifedipine can&#x000a0;lead to systemic vasodilation, severe hypotension, and reflex tachycardia.&#x000a0;Prolonged systemic hypotension can progress to shock and even death. Activated charcoal at a dose of 1 g/kg is useful if the patient presents within 1 to 2 hours of ingestion. Whole bowel irrigation should be a consideration with extended-release preparations or large quantity ingestion. Nasogastric lavage is usually ineffective. Intravenous fluid resuscitation, calcium salts, and vasopressor therapy with dopamine or norepinephrine usually alleviate the hypotension. Administration of high-dose insulin is an option as it has been shown to lower mortality and improve hemodynamics. Electrocardiographic results, vital signs, kidney function, urine output, and electrolytes require continuous monitoring. For intentional ingestion, psychiatric consultation is also necessary. Patients presenting with an overdose of immediate-release preparations need observation for 4 to 7 hours. For extended-release preparations, 24 hours of telemetry observation is ideal.</p>
        <p>No specific antidote is available.&#x000a0;</p>
      </sec>
      <sec id="article-25883.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All interprofessional healthcare team members&#x000a0;should be familiar with the indications and contraindications of nifedipine. This includes all clinicians (including specialists, NPs, and PAs), nurses, and pharmacists. The drug can cause severe hypotension, and thus it is recommended that&#x000a0;the dosing undergo titration from an initial low dose.&#x000a0;Long-term patient monitoring is necessary to determine its effectiveness. Sublingual preparations are no longer recommended agents for hypertensive emergencies or urgencies due to lack of efficacy data and numerous severe adverse events such as&#x000a0;an uncontrollable decrease in blood pressure, reflex tachycardia, and cerebral ischemia/infarction.</p>
        <p>Given the risks, prescribing/ordering clinicians should strive to work with&#x000a0;the interprofessional team when using nifedipine. Pharmacists should have involvement to verify dosing, particularly with the dosing differences between release formulations. They also need to conduct medication reconciliation to alert the team to any potential drug-drug interactions. Nurses will be administering the drug inpatient and are on the front lines for observing both treatment effectiveness as well as adverse events, which they should report to the clinician immediately. This collaborative interprofessional approach between clinicians, nursing, and pharmacy will better advance patient outcomes with nifedipine therapy. [Level 5]</p>
      </sec>
      <sec id="article-25883.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25883&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25883">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25883/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25883">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25883.s11">
        <title>References</title>
        <ref id="article-25883.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherman</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Nifedipine in chronic stable angina: a double-blind placebo-controlled crossover trial.</article-title>
            <source>Am J Cardiol</source>
            <year>1983</year>
            <month>Mar</month>
            <day>01</day>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>706</fpage>
            <page-range>706-11</page-range>
            <pub-id pub-id-type="pmid">6402914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savonitto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ardissiono</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Egstrup</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Omland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schjelderup-Mathiesen</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Marraccini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wahlqvist</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rehnqvist</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1996</year>
            <month>Feb</month>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-6</page-range>
            <pub-id pub-id-type="pmid">8557899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dargie</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Krikler</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krikler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nifedipine and propranolol: a beneficial drug interaction.</article-title>
            <source>Am J Med</source>
            <year>1981</year>
            <month>Oct</month>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>676</fpage>
            <page-range>676-82</page-range>
            <pub-id pub-id-type="pmid">7025625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1269</fpage>
            <page-range>1269-1324</page-range>
            <pub-id pub-id-type="pmid">29133354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shekhar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kirubakaran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pareek</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis.</article-title>
            <source>BJOG</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-7</page-range>
            <pub-id pub-id-type="pmid">26113232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <collab>Committee on Obstetric Practice</collab>
            <article-title>Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.</article-title>
            <source>Obstet Gynecol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>e90</fpage>
            <page-range>e90-e95</page-range>
            <pub-id pub-id-type="pmid">28333820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <collab>American College of Cardiology Foundation</collab>
              <collab>American Heart Association Task Force on Practice Guidelines</collab>
              <collab>American College of Emergency Physicians</collab>
              <collab>Society for Cardiovascular Angiography and Interventions</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>E1</fpage>
            <page-range>E1-27</page-range>
            <pub-id pub-id-type="pmid">23299937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luks</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Grissom</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Auerbach</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Rodway</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Schoene</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Zafren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>PH</given-names>
              </name>
              <collab>Wilderness Medical Society</collab>
            </person-group>
            <article-title>Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update.</article-title>
            <source>Wilderness Environ Med</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>4 Suppl</issue>
            <fpage>S4</fpage>
            <page-range>S4-14</page-range>
            <pub-id pub-id-type="pmid">25498261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez Sanchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klepetko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Zompatori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>M</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jan</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-119</page-range>
            <pub-id pub-id-type="pmid">26320113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>QF</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>252</fpage>
            <page-range>252-261</page-range>
            <pub-id pub-id-type="pmid">30582271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic.</article-title>
            <source>BJU Int</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>276</fpage>
            <page-range>276-9</page-range>
            <pub-id pub-id-type="pmid">21083640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rirash</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tingey</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Maxwell</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tanjong Ghogomu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tugwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pope</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blockers for primary and secondary Raynaud's phenomenon.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Dec</month>
            <day>13</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD000467</fpage>
            <pub-id pub-id-type="pmid">29237099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kilpatrick</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Postpartum Hypertension: Etiology, Diagnosis, and Management.</article-title>
            <source>Obstet Gynecol Surv</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-252</page-range>
            <pub-id pub-id-type="pmid">28426127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25883.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The use of sublingual nifedipine: a continuing concern.</article-title>
            <source>Arch Intern Med</source>
            <year>1999</year>
            <month>Oct</month>
            <day>25</day>
            <volume>159</volume>
            <issue>19</issue>
            <fpage>2259</fpage>
            <page-range>2259-60</page-range>
            <pub-id pub-id-type="pmid">10547164</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
